Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era

We measured severe acute respiratory syndrome coronavirus 2 immunoglobulin G responses in 67 patients with hematological malignancies after 2 messenger RNA vaccine doses. Forty-six percent were nonresponders; patients with B-cell chronic lymphocytic leukemia were at highest risk (77% nonresponders)....

Descripción completa

Detalles Bibliográficos
Autores principales: Agha, Mounzer E, Blake, Maggie, Chilleo, Charles, Wells, Alan, Haidar, Ghady
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320282/
https://www.ncbi.nlm.nih.gov/pubmed/34337100
http://dx.doi.org/10.1093/ofid/ofab353
_version_ 1783730619851735040
author Agha, Mounzer E
Blake, Maggie
Chilleo, Charles
Wells, Alan
Haidar, Ghady
author_facet Agha, Mounzer E
Blake, Maggie
Chilleo, Charles
Wells, Alan
Haidar, Ghady
author_sort Agha, Mounzer E
collection PubMed
description We measured severe acute respiratory syndrome coronavirus 2 immunoglobulin G responses in 67 patients with hematological malignancies after 2 messenger RNA vaccine doses. Forty-six percent were nonresponders; patients with B-cell chronic lymphocytic leukemia were at highest risk (77% nonresponders). Patients with hematological malignancies should continue wearing masks and socially distancing. Studies of revaccination, boosters, and humoral immune correlates of protection are needed.
format Online
Article
Text
id pubmed-8320282
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-83202822021-07-30 Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era Agha, Mounzer E Blake, Maggie Chilleo, Charles Wells, Alan Haidar, Ghady Open Forum Infect Dis Brief Reports We measured severe acute respiratory syndrome coronavirus 2 immunoglobulin G responses in 67 patients with hematological malignancies after 2 messenger RNA vaccine doses. Forty-six percent were nonresponders; patients with B-cell chronic lymphocytic leukemia were at highest risk (77% nonresponders). Patients with hematological malignancies should continue wearing masks and socially distancing. Studies of revaccination, boosters, and humoral immune correlates of protection are needed. Oxford University Press 2021-06-30 /pmc/articles/PMC8320282/ /pubmed/34337100 http://dx.doi.org/10.1093/ofid/ofab353 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Reports
Agha, Mounzer E
Blake, Maggie
Chilleo, Charles
Wells, Alan
Haidar, Ghady
Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era
title Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era
title_full Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era
title_fullStr Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era
title_full_unstemmed Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era
title_short Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era
title_sort suboptimal response to coronavirus disease 2019 messenger rna vaccines in patients with hematologic malignancies: a need for vigilance in the postmasking era
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320282/
https://www.ncbi.nlm.nih.gov/pubmed/34337100
http://dx.doi.org/10.1093/ofid/ofab353
work_keys_str_mv AT aghamounzere suboptimalresponsetocoronavirusdisease2019messengerrnavaccinesinpatientswithhematologicmalignanciesaneedforvigilanceinthepostmaskingera
AT blakemaggie suboptimalresponsetocoronavirusdisease2019messengerrnavaccinesinpatientswithhematologicmalignanciesaneedforvigilanceinthepostmaskingera
AT chilleocharles suboptimalresponsetocoronavirusdisease2019messengerrnavaccinesinpatientswithhematologicmalignanciesaneedforvigilanceinthepostmaskingera
AT wellsalan suboptimalresponsetocoronavirusdisease2019messengerrnavaccinesinpatientswithhematologicmalignanciesaneedforvigilanceinthepostmaskingera
AT haidarghady suboptimalresponsetocoronavirusdisease2019messengerrnavaccinesinpatientswithhematologicmalignanciesaneedforvigilanceinthepostmaskingera

Ejemplares similares